Alert

Recommended Alerts

Sign Up For Alerts

Can They Really Do That? The Specter of Government-Authorized Infringement of Pharmaceutical Patents

The perception that pharmaceuticals in the United States are overpriced, and that patent rights are why, has been a recurrent political theme over the last several years. This view, along with the ongoing novel coronavirus pandemic, has caused some to consider whether the U.S. government should act to ensure affordable access to potentially life-saving medicines.

Read More

Supreme Court Rejects Bright-Line Test For Materiality in Rule 10b-5 Class Action With Respect to Adverse Event Reports

Practices: Life Sciences, Corporate & Securities Litigation, Securities & Public Companies

Printer-Friendly Version

Cookie Settings